What is Genfit?
Founded in 1999 and headquartered in Loos, Hauts-de-France, Genfit operates at the intersection of biotechnology and pharmaceutical innovation. The firm specializes in the discovery and development of novel therapeutic and diagnostic candidates designed to treat metabolic and inflammatory diseases, which represent significant unmet medical needs. Through a rigorous scientific approach, Genfit has established a robust portfolio that bridges the gap between early-stage research and commercial-ready medical solutions. Its market position is defined by a focus on high-impact therapeutic areas, where its proprietary technology platforms aim to improve patient outcomes and redefine standards of care in chronic disease management.
How much funding has Genfit raised?
Genfit has raised a total of $703M across 13 funding rounds:
Share Placement
$15.5M
Share Placement
$5.4M
Share Placement
$22.7M
Share Placement
$36.6M
Share Placement
$48.2M
Debt
$194.5M
Stock Offering
$155.4M
Debt
$13.3M
Debt
$200M
Share Placement (2013): $15.5M, investors not publicly disclosed
Share Placement (2014): $5.4M, investors not publicly disclosed
Share Placement (2014): $22.7M, investors not publicly disclosed
Share Placement (2016): $36.6M, investors not publicly disclosed
Share Placement (2016): $48.2M, investors not publicly disclosed
Debt (2017): $194.5M, investors not publicly disclosed
Stock Issuance/Offering (2019): $155.4M, investors not publicly disclosed
Debt (2021): $13.3M led by The French Government
Debt (2025): $200M supported by HealthCare Royalty Management
Key Investors in Genfit
HealthCare Royalty Management
HealthCare Royalty is a specialized investment firm that provides capital solutions to the biopharmaceutical sector through the acquisition of royalty interests and tailored financing arrangements.
OSEO
A French public institution dedicated to supporting the growth and innovation of small and medium-sized enterprises through various financing and guarantee mechanisms.
YA Global Master SPV Ltd
An investment vehicle associated with Yorkville Advisors, focusing on providing flexible capital solutions to growth-oriented companies across various sectors.
What's next for Genfit?
With the recent capital injection, Genfit is strategically positioned to advance its late-stage clinical assets and optimize its operational efficiency. The company is expected to prioritize the commercialization of its lead programs, leveraging the non-dilutive nature of its recent debt financing to maintain shareholder value while scaling its infrastructure. Future growth will likely be driven by the successful execution of clinical trials and the potential expansion of its diagnostic portfolio. As Genfit navigates the complexities of the global biopharmaceutical market, this strategic financing provides the runway required to achieve key regulatory milestones and sustain its long-term mission of delivering transformative medical therapies to patients worldwide.
See full Genfit company page
